MEXITIL Drug Patent Profile

When do Mexitil patents expire, and what generic alternatives are available?

Mexitil is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in MEXITIL is mexiletine hydrochloride. There are five drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mexiletine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mexitil

A generic version of MEXITIL was approved as mexiletine hydrochloride by TEVA on May 16^th, 1995.

Summary for MEXITIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	173
Clinical Trials:	4
Patent Applications:	4,514
DailyMed Link:	MEXITIL at DailyMed

Recent Clinical Trials for MEXITIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 2
Food and Drug Administration (FDA)	Phase 1
Spaulding Clinical Research LLC	Phase 1

See all MEXITIL clinical trials

US Patents and Regulatory Information for MEXITIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985		DISCN	Yes	No
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985		DISCN	Yes	No
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985		DISCN	Yes	No

Expired US Patents for MEXITIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985	3,954,872
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985	4,031,244
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985	3,954,872
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985	4,031,244
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985	3,954,872
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985	4,031,244

International Patents for MEXITIL

See the table below for patents covering MEXITIL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	291225
Austria	289075
France	1551055
Italy	7949431
Switzerland	509251	Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminoalkane
Switzerland	518259	Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminoalkane
Germany	1643240

Last updated: April 25, 2026

MEXITIL: Market Dynamics and Financial Trajectory

Mexitil (mexiletine) is an older, non-oncology, oral antiarrhythmic used mainly for ventricular arrhythmias and managed care reliance. The market dynamics are shaped by (1) limited label expansions, (2) aging prescriber base, (3) generic competition as patent life has long ended, and (4) price compression typical of off-patent cardiovascular small molecules in the US and EU. Financial trajectory is therefore dominated by unit volume resilience rather than premium pricing, with revenue growth, when it occurs, tied to formulary access and channel execution rather than new clinical differentiation.

What is MEXITIL’s commercial foundation (indication and positioning)?

Mexitil (mexiletine hydrochloride) is marketed for treatment of ventricular arrhythmias, including in patients intolerant of or inadequately controlled on other antiarrhythmics. Commercially, it sits in the “maintenance cardiovascular” category rather than acute or specialty care.

Core commercial implications

• Long product lifecycle, low innovation cadence: As an older molecule, it does not rely on blockbuster trial cycles to renew demand.
• Generic-driven pricing: Where generics are available, branded sales typically fall to niche segments or to periods of temporary supply imbalance.
• Medical necessity and formulary gatekeeping: Sustained demand depends on plan coverage, substitution rules, and prior authorization patterns in cardiology drug pathways.

How do market dynamics typically shape demand for mexiletine?

Mexiletine demand behaves like other off-patent antiarrhythmics: stable but not rapidly expanding, sensitive to payer policy and patient persistence.

Key demand drivers

• Formulary access (managed care): Coverage decisions in cardiovascular formularies influence net demand, especially when generics undercut branded WAC.
• Substitution and pharmacy switching: Generic availability reduces branded share unless prescribers specify brand or patient history blocks substitution.
• Clinical inertia and persistence: Patients stabilized on mexiletine can remain on therapy, supporting baseline continuity even as new patients are harder to recruit.
• Short-term supply constraints: Any manufacturing or distribution disruption can shift demand temporarily toward brands or alternate NDCs.

Key headwinds

• Price compression: After generic entry, branded pricing power collapses and overall category pricing trends toward the generic benchmark.
• Limited differentiation: No new mechanism or formulation-driven reclassification that would create specialty premiums.
• Slow uptake in emerging practices: Newer antiarrhythmic pathways and procedural management can reduce mexiletine initiation rates over time.

What does the competitive landscape imply for pricing and margins?

Because mexiletine’s branded period has passed, pricing and margins are anchored to the generic reference price. The branded product’s financial performance, if it persists, tends to reflect a residual share and lifecycle management (contracting and rebates).

Competition structure

• Generic mexiletine tablets in most major markets typically drive the benchmark price.
• Branded MEXITIL is usually forced into competitiveness through rebates and contracting rather than headline price.

Commercial effect

• Net pricing becomes rebate- and contract-dependent.
• Revenue growth is more tied to share and access than to unit price.

How has the regulatory position affected market trajectory?

For market trajectory, the critical factor is whether mexiletine has experienced meaningful label expansion or safety-driven restrictions. For older cardiovascular drugs, regulatory actions typically cause step-change demand impacts only when they alter coverage and prescribing norms.

• If label remains stable: demand tracks category trends and generics pricing pressure.
• If restrictions or safety communications occur: utilization can shift quickly and then stabilize at a lower baseline.
• If formulation or bioavailability changes occur: they can temporarily influence brand share during transition periods.

(Absent label expansion or major restrictions, the financial trajectory remains mostly a lifecycle and contracting story.)

What is the expected financial trajectory pattern for MEXITIL under generic dominance?

Under generic dominance, branded revenue typically follows a decay-and-stabilize pattern, with variability driven by formulary dynamics, contracting, and supply.

Common revenue shape (branded under generics)

• Early post-generic period: sharp decline as substitution accelerates.
• Mid lifecycle: stabilization at a lower run-rate, supported by medical necessity exceptions and prescriber brand preference in a subset of patients.
• Late lifecycle: flat to slightly declining revenues, with potential bursts from supply disruptions or contracting changes.

Likely KPIs that govern performance

• Net sales by channel: pharmacy chain, mail order, hospital outpatient purchasing.
• Share of prescriptions vs share of spending: a branded brand can maintain prescription share in certain segments but still lose spending share to rebates and generic substitution.
• Patient persistence: time on therapy for stabilized arrhythmia patients.
• Contract coverage: number of covered lives and formulary tier placement.

What are the business levers that can still move revenues?

Even without patent-protected pricing, branded mexiletine can still move results through execution rather than innovation.

Primary levers

• Managed care contracting: securing coverage and tier placement reduces loss to generics.
• Distribution reliability: preventing stock-outs protects residual share.
• Medical affairs support tied to formularies: addressing coverage criteria and prior authorization patterns can slow share erosion.
• Brand substitution safeguards: targeting prescriber segments where substitution is less likely to occur.

Key takeaways on market and financial trajectory

• MEXITIL is structurally exposed to generic pricing compression, so revenue trajectory is driven by access and share rather than premium pricing.
• Demand stability is more plausible than growth because mexiletine treats a chronic management condition and depends on persistence, not new patient acquisition at scale.
• Financial performance should be modeled as a residual-brand business: declining from pre-generic levels and then flattening, with variability from contracting and supply.

FAQs

1) Is MEXITIL expected to be a growth driver in pharma portfolios?

No. Under generic dominance, branded mexiletine typically functions as a residual sales stream governed by formulary access and contracting.

2) What most influences branded MEXITIL net revenue?

Managed care contracting, rebate structures, formulary tier placement, and pharmacy substitution patterns.

3) How do supply constraints affect MEXITIL sales?

Short-term disruptions can temporarily shift demand toward the brand or toward specific available NDCs, creating brief revenue uplifts.

4) Do new clinical guidelines usually raise or lower mexiletine demand?

They can shift prescribing patterns. Without label expansion or major safety-driven changes, guideline evolution typically changes initiation rates more than persistence in established patients.

5) What does “market dynamics” mean for mexiletine specifically?

It means off-patent pricing pressure, payer gatekeeping, substitution rules, and patient persistence determine the revenue curve more than innovation cycles.

---

References

[1] FDA. Drug Labeling: Mexiletine (MEXITIL) prescribing information. (Accessed via FDA labeling database).